Bevacizumab-based therapy for advanced small bowel adenocarcinoma

Several articles in Gut have highlighted the predisposition to small bowel carcinogenesis caused by either mismatch repair gene mutations 1 or chronic mucosal wounding by conditions such as Crohn's disease 2 or coeliac sprue. 3 Small bowel damage of the latter kind is associated with induction...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2008-11, Vol.57 (11), p.1631-1632
Hauptverfasser:	Tsang, H, Yau, T, Khong, P L, Epstein, R J
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdomen Adenocarcinoma - drug therapy Aged Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Cytotoxicity Female Humans Intestinal Neoplasms - drug therapy Intestine, Small Lymphatic system Rodents Transforming Growth Factor beta1 - metabolism Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Several articles in Gut have highlighted the predisposition to small bowel carcinogenesis caused by either mismatch repair gene mutations 1 or chronic mucosal wounding by conditions such as Crohn's disease 2 or coeliac sprue. 3 Small bowel damage of the latter kind is associated with induction of the proangiogenic peptide, vascular endothelial growth factor (VEGF), 4 which is in turn accompanied by expression of proinflammatory cyclo-oxygenases and the wound healing cytokine transforming growth factor Î².
ISSN:	0017-5749 1468-3288
DOI:	10.1136/gut.2008.153866